Bromopride

Bromopride

SCHEMBL54497

CCN(CC)CCNC(=O)c1cc(Br)c(N)cc1OC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

DRD2

The experimentally established mechanism targets of Bromopride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 known ✓ P14416 2/20 0.74
ADRA2A P08913 3/20 1.00
CYP2D6 P10635 3/20 1.00
DRD3 P35462 3/20 1.00
CYP1A2 P05177 2/20 1.00
HTR1A P08908 1/20 1.00
DRD1 P21728 1/20 1.00
ACHE P22303 1/20 1.00
PTGS1 P23219 1/20 1.00
LMNA P02545 3/20 0.74
HTR2B P41595 2/20 0.74
KCNH2 Q12809 2/20 0.74
ALDH1A1 P00352 2/20 0.74
HTR3E A5X5Y0 1/20 0.74
SLC22A1 O15245 1/20 0.74
HTR3B O95264 1/20 0.74
MPO P05164 1/20 0.74
ADRA2C P18825 1/20 0.74
DRD4 P21917 1/20 0.74
HTR2A P28223 1/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromopride SCHEMBL8385045 0.99 ADRA2A (0.98) ADRA2ACYP2D6DRD3CYP1A2HTR1A
Bromopride SCHEMBL18338829 0.98 ADRA2A (0.95) ADRA2ACYP2D6DRD3CYP1A2HTR1A
Bromopride SCHEMBL1648933 0.98 ADRA2A (0.95) ADRA2ACYP2D6DRD3CYP1A2HTR1A
Bromopride SCHEMBL18339178 0.98 ADRA2A (0.95) ADRA2ACYP2D6DRD3CYP1A2HTR1A
SCHEMBL11946667 0.86 ADRA2A (0.76) ADRA2ACYP2D6DRD3CYP1A2HTR1A
SCHEMBL17068280 0.86 ADRA2A (0.76) ADRA2ACYP2D6DRD3CYP1A2HTR1A
Bromopride SCHEMBL12497087 0.86 ADRA2A (0.73) ADRA2ACYP2D6DRD3CYP1A2HTR1A
SCHEMBL3415873 0.85 ADRA2A (0.74) ADRA2ACYP2D6DRD3CYP1A2HTR1A
SCHEMBL2624889 0.85 ADRA2A (0.74) ADRA2ACYP2D6DRD3CYP1A2HTR1A
Metoclopramide SCHEMBL18629 0.85 HTR4 (1.00) ADRA2ACYP2D6DRD3CYP1A2HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 3408 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025122610-A1 THERAPEUTIC COMBINATIONS AND METHODS FOR 5-HT3 RECEPTOR MODULATORS IN TREATING VARIOUS DISORDERS SEROTONIX LLC (US) 2025-06-12 WO claimed
WO-2025111482-A1 COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS BEXSON BIOMEDICAL, INC. (US) 2025-05-30 WO claimed
US-20240366639-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO INC (US) 2024-11-07 US claimed
US-20230414702-A1 COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER PEPKON SAS (FR) 2023-12-28 US claimed
CN-116660543-A Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof 中国人民解放军陆军军医大学第一附属医院 2023-08-29 CN claimed
EP-4178948-A2 FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF Universidade de Santiago de Compostela (ES) 2023-05-17 EP claimed
WO-2023049482-A1 METHODS OF TREATING RESTRICTIVE EATING DISORDERS ARVID THERAPEUTICS (US) 2023-03-30 WO claimed
WO-2023016546-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. (US) 2023-02-16 WO claimed
EP-4035668-A1 ANTICHOLINERGIC NEUROPROTECTIVE COMPOSITION AND METHODS Chase Pharmaceuticals Corporation (US) 2022-08-03 EP claimed
WO-2022023496-A2 FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) 2022-02-03 WO claimed
WO-2002007706-A1 METHOD FOR COATING SOLID PARTICLES WITH A THERMOFUSIBLE AGENT, AND RESULTING COATED SOLID PARTICLES GATTEFOSSE HOLDING (FR) 2002-01-31 WO claimed
WO-2001034232-A1 INHALATION NEBULIZER Pari GmbH Spezialisten für effektive Inhalation (DE) 2001-05-17 WO claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000051563-A1 PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION COMPRISING A BENZAMIDE AND AT LEAST AN ABSORPTION PROMOTER SANOFI-SYNTHELABO (FR) 2000-09-08 WO claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
EP-0695172-B1 HIGH RELEASE SOLID PREPARATION, PREPARATION AND USE THEREOF UNIV GENT (BE) 1997-12-17 EP claimed
EP-0695172-A1 HIGH RELEASE SOLID PREPARATION, PREPARATION AND USE THEREOF RIJKSUNIVERSITEIT GENT LABORATORIUM VOOR FARMACEUTISCHE TECHNOLOGIE (BE) 1996-02-07 EP claimed
WO-1994023700-A1 HIGH RELEASE SOLID PREPARATION, PREPARATION AND USE THEREOF RIJKSUNIVERSITEIT GENT LABORATORIUM VOOR FARMACEUTISCHE TECHNOLOGIE (BE) 1994-10-27 WO claimed
EP-0274708-B1 MEDICINE FOR HYPOGLYCEMIA ADMINISTRATION Bergis, Kristian, Dr. (DE) 1992-05-13 EP claimed